Combined Losartan (L) and Hydrocholorothyazide (H) treatment (LH) prevents progression of chronic kidney disease (CKD) resulting from L treatment during lactation (LLac) (2010)
- Authors:
- USP affiliated authors: FANELLI, CAMILLA - FM ; FERNANDES, BIANCA HELENA VENTURA - FM ; FUJIHARA, CLARICE KAZUE - FM ; ZATZ, ROBERTO - FM
- Unidade: FM
- Subjects: RIM (PATOLOGIA); DOENÇA CRÔNICA (TERAPIA;PREVENÇÃO E CONTROLE); HIPERTENSÃO (PREVENÇÃO E CONTROLE); RESUMOS (EVENTOS)
- Language: Inglês
- Imprenta:
- Source:
- Conference titles: Simpósio "Avanços em Pesquisas Médicas dos Laboratórios de Investigação Médica do Hospital das Clínicas da FMUSP"
-
ABNT
FANELLI, Camila et al. Combined Losartan (L) and Hydrocholorothyazide (H) treatment (LH) prevents progression of chronic kidney disease (CKD) resulting from L treatment during lactation (LLac). Clinics. São Paulo: Faculdade de Medicina, Universidade de São Paulo. . Acesso em: 19 abr. 2024. , 2010 -
APA
Fanelli, C., Fernandes, B. H. V., Machado, F. G., Poppi, E. P. B., Malheiros, D. M. A. C., Fujihara, C. K., & Zatz, R. (2010). Combined Losartan (L) and Hydrocholorothyazide (H) treatment (LH) prevents progression of chronic kidney disease (CKD) resulting from L treatment during lactation (LLac). Clinics. São Paulo: Faculdade de Medicina, Universidade de São Paulo. -
NLM
Fanelli C, Fernandes BHV, Machado FG, Poppi EPB, Malheiros DMAC, Fujihara CK, Zatz R. Combined Losartan (L) and Hydrocholorothyazide (H) treatment (LH) prevents progression of chronic kidney disease (CKD) resulting from L treatment during lactation (LLac). Clinics. 2010 ; 65 S55.[citado 2024 abr. 19 ] -
Vancouver
Fanelli C, Fernandes BHV, Machado FG, Poppi EPB, Malheiros DMAC, Fujihara CK, Zatz R. Combined Losartan (L) and Hydrocholorothyazide (H) treatment (LH) prevents progression of chronic kidney disease (CKD) resulting from L treatment during lactation (LLac). Clinics. 2010 ; 65 S55.[citado 2024 abr. 19 ] - Combined losartan and hydrochlorothiazide prevents progression of renal injury in chronic nephropathy resulting from losartan treatment
- Regressão da nefropatia diabética experimental: Ausência de efeito dose resposta de um antagonista da angiotensina II
- Regression of diabetic nephropathy: no dose-response effect of an angiotensin II antagonist
- High-dose losartan (L) provides no additional protection in a model of chronic kidney disease (CKD) caused by L treatment during lactation (LLac)
- Renoprotective effect of two dosages of Losartan (L) in a model of crhonic kidney disease (CDK) by nitric oxide inhibition and and salt overload
- Losartan (L) and hydrochlorotiazide (H) association (LH) arrests renal inhury in a model of very advanced chronic kidney disease (CKD)
- Losartan (L) and Hydrochlorothiazide (H)Treatment (LH) arrests renal and cardiac injury in advanced chronic kidney disease by mechanisms not entireky dependent on blood pressure
- Furosemide (F) is less effective than hydroclorothiazide (H) as adjuvant to losartan (L) in arresting the nephropathy associated with the 5/6 renal ablation model (NX)
- Hydrochlorothiazide and losartan in combination prevent progressive nephropathy in the 5/6 renal ablation model
- Associação terapêutica de losartan (L) e hidroclorotiazida (H) previne progressão da lesão renal em modelo de nefropatia crônica resultante da administração de (L) durante a lactação
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
